Australia's most trusted
source of pharma news
Posted 21 January 2025 AM
A patient support program offering financial help to access fertility services has landed Vertex in hot water with the US Department of Health and Human Services (HHS) which has accused the company of attempting to violate anti-kickback laws.
A court case in the US District Court of Columbia has thrown the company's gene therapy Casgevy, for sickle cell disease and transfusion-dependent beta-thalassaemia into the spotlight for all the wrong reasons, and offers a masterclass into how a patient program, no matter how well-intentioned, can backfire.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.